AbCellera partners with researchers to accelerate the development of antibody therapies and vaccines. Their single-cell platform combines immunizations, imaging, genomics, and computation to screen for natural immune responses and antibody production. Their proprietary software, Celium, helps analyze and visualize large amounts of data. AbCellera is also working on developing medical countermeasures for viral pathogens, including SARS-CoV-2. They have received funding from various sources, including the Bill & Melinda Gates Foundation.